Can-Fite: Muscling up on A3

Building on the observation that tumors rarely spread to muscle tissue, Can-Fite BioPharma Ltd. is developing small molecule adenosine receptor modulators that are active against cancer and inflammatory diseases such as rheumatoid arthritis. The company's most advanced compound, CF101, is a specific adenosine A3 receptor agonist in an ongoing Phase IIa trial for RA.

"Our founding scientist and chief scientific officer,

Read the full 607 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE